Application No.: 09/872,384

3

Docket No.: 282172000810

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended):

A method of treating a blood product which contains a nucleic acid containing pathogen to be inactivated, said method comprising

- a) adding psoralen to the blood product;
- b) irradiating the psoralen and the blood product to form under conditions

 effective for said psoralen to inactivate said pathogen, thereby forming a mixture comprising said

 blood product, inactivated pathogen, free psoralen, and low molecular weight psoralen

 photoproducts; and
- c) contacting said mixture with a hypercrosslinked resin to remove at least substantially all of said free psoralen and said low molecular weight psoralen photoproducts.

Claim 2 (original): The method of claim 1 wherein said psoralen comprises an aminopsoralen selected from the group consisting of 4'-primary amino-substituted psoralen and 5'-primary amino-substituted psoralen.

Claim 3 (original): The method of claim 1 wherein said blood product comprises plasma.

Claim 4 (original): The method of claim 1 wherein said hypercrosslinked resin is not pre-wetted prior to said act of contacting said mixture with said hypercrosslinked resin.

Claim 5 (original): The method of claim 1 wherein said hypercrosslinked resin comprises a polyaromatic resin that is capable of adsorbing said free psoralen and said low molecular weight psoralen photoproducts.

Claim 6 (original): The method of claim 5 wherein said psoralen comprises an aminopsoralen selected from the group consisting of 4'-primary amino-substituted psoralen and 5'-primary amino-substituted psoralen.

ра-946662

Application No.: 09/872,384

4

Docket No.: 282172000810

Claim 7 (original): The method of claim 6 wherein said aminopsoralen comprises 4'-(4-amino-2-oxa)butyl-4,5',8-trimethylpsoralen.

Claim 8 (currently amended): A method of removing free psoralen free in solution from a biological fluid comprising blood or a blood product, said free psoralen having been exposed to light having a wavelength and in an amount sufficient to cause a pathogen to be inactivated by said psoralen, that eauses psoralen to covalently bind to a nucleic acid, the method comprising contacting said biological fluid with a hypercrosslinked adsorbent resin that is capable of removing said free psoralen; and removing at least substantially all of said free psoralen from said biological fluid with said hypercrosslinked adsorbent resin.

Claim 9 (original): The method of claim 8 wherein said resin is selected from the group consisting of: a polyaromatic resin having a mean surface area of about 1100 m²/gm, a mean pore diameter of about 46Å, and a mesh size of about 20-50µm; a polyaromatic resin having a mean surface area of about 725 m²/gm, a mean pore diameter of about 40Å, and a mesh size of about 20-60µm; and a functionalized polyaromatic resin having a mean surface area of about 800 m²/gm, a mean pore diameter of about 25Å, and a mesh size of about 20-50µm.

Claim 10 (original): The method of claim 8 wherein said biological fluid comprises a plasma' blood product.

Claim 11 (original): The method of claim 8 wherein said biological fluid comprises a platelet-containing blood product.

Claim 12 (original): The method of claim 11 wherein said biological fluid further comprises a synthetic medium containing phosphate.

Claim 13 (original): The method of claim 8 wherein said resin is not pre-wetted prior to contacting said biological fluid with said resin.

Application No.: 09/872,384

5

Docket No.: 282172000810

Claim 14 (original): The method of claim 8 wherein said psoralen comprises an aminopsoralen selected from the group consisting of 4'-primary amino-substituted psoralen and 5'-primary amino-substituted psoralen.

Claim 15 (original): The method of claim 14 wherein said aminopsoralen comprises 4'-(4-amino-2-oxa)butyl-4,5',8-trimethylpsoralen.

Claim 16 (original): The method of claim 8 wherein said hypercrosslinked resin comprises a hypercrosslinked polyaromatic resin.

Claim 17 (original): The method of claim 16 wherein said biological fluid is selected from the group consisting of plasma and platelets.

Claim 18 (original): The method of claim 16 wherein said psoralen comprises an aminopsoralen selected from the group consisting of 4'-primary amino-substituted psoralen and 5'-primary amino-substituted psoralen.

Claim 19 (withdrawn): The method of claim 16 wherein said psoralen comprises a brominated psoralen.

Claim 20 (amended): The method of claim 16 wherein the biological fluid further comprises <u>low</u> molecular weight psoralen photo products, and wherein said resin additionally removes at least substantially all of said <u>low molecular weight</u> psoralen photo products.

Claim 21 (original): A biological fluid formed by the method of claim 1.

Claim 22 (original): A biological fluid formed by the method of claim 3.

Claim 23 (original): A biological fluid formed by the method of claim 8.

Claim 24 (original): A biological fluid formed by the method of claim 12.

Claim 25 (new): The method of claim 1 wherein said blood product comprises platelets.

pa-946662